A recent statistic has caught the attention of Bank of America (BofA) analysts, who have reaffirmed their positive outlook for Gilead Sciences. The biotech firm continues to push forward with its HIV vaccine research and development, showing substantial growth in the field.
According to BofA, more than 70% of clinical trials have achieved key success rates, a notable statistic in support of Gilead's prospects in the sector.
The optimistic outlook from BofA analysts has bolstered investor confidence in Gilead Sciences amid ongoing clinical trials and advancements in HIV treatment.